I-Mab logo
I-Mab IMAB
report update icon

Annual report 2025
added 06-16-2026

I-Mab Balance Sheet 2025-2011 | IMAB

Brief overview of I-Mab's balance sheet structure

This overview follows the five latest available annual observations between 2018 and 2023.

Assets grew from 2.4 billion CNY to 2.6 billion CNY. An increase of +10% at roughly 1.9% CAGR was not especially fast.

Liability growth of +115.3% exceeded asset growth of +10%, increasing reliance on outside funding.

The equity-to-assets ratio is 65.8%, compared with -40.2% five periods ago. The balance sheet has a substantial internal cushion.

The period ended with net cash: net debt stood at -2.1 billion CNY. This supports financial flexibility.

The cash reserve occupies 82% of the balance sheet, previously 70.7%. It is one marker of short-term resilience.

The accumulated result is -8.3 billion CNY and remains below zero. The number alone does not explain whether losses, dividends or repurchases were the main cause.

What the balance sheet shows

I-Mab's balance sheet is broadly resilient, though selected areas require monitoring. The balance between assets, equity and liabilities remains the key issue.

Annual Balance Sheet I-Mab

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Net Debt

- - -2.1 B -3.16 B - - -1.06 B -1.61 B -94.9 M - - - - - -

Long Term Debt

- - 23.1 M 32.1 M - - 68.2 M 67 M 114 M - - - - - -

Long Term Debt Current

- - 21.9 M 24 M - 8.06 M 6.81 M - - - - - - - -

Total Non Current Liabilities

- - - - - 131 M 79.6 M 2.98 B 1.13 B - - - - - -

Total Current Liabilities

- - 412 M 758 M - 576 M 588 M 346 M - - - - - - -

Total Liabilities

- - 895 M 1.16 B - 707 M 668 M 416 M 1.33 B - - - - - -

Deferred Revenue

- - 2.2 M 8.68 M - - 563 K 14.2 M 15.8 M - - - - - -

Retained Earnings

- - -8.33 B -6.86 B -4.35 B -2.02 B -2.49 B -1.01 B -358 M - - - - - -

Total Assets

- - 2.61 B 4.07 B - 6.33 B 1.74 B 2.38 B 1.03 B - - - - - -

Cash and Cash Equivalents

- - 2.14 B 3.21 B - 4.76 B 1.14 B 1.68 B 413 M - - - - - -

Book Value

- - 1.72 B 2.91 B - 5.63 B 1.07 B 1.96 B -300 M - - - - - -

Total Shareholders Equity

- - 1.72 B 2.91 B 4.56 B 5.63 B -2.03 B -955 M -300 M - - - - - -

All numbers in CNY currency

Quarterly Balance Sheet I-Mab

2025-Q4 2025-Q3 2025-Q2 2024-Q4 2023-Q4 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Long Term Debt

- - - - - - - - - 81.8 M - - - 5.54 M 5.18 M - - 7.49 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Liabilities

- - - - 895 M 1.16 B - 975 M - 1.04 B - - - 707 M 556 M - - 668 M - - - 416 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Deferred Revenue

- - - - - - - - - - - - - - - - - - - - - 14.2 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Retained Earnings

- - - - -8.33 B -6.86 B - -5.4 B - -4.35 B - - - -2.02 B -3.06 B - - -2.49 B - - - -1.01 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Assets

- - - - 2.61 B 4.07 B - 4.99 B - 5.6 B - - - 6.33 B 4.3 B - - 1.74 B - - - 2.38 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Cash and Cash Equivalents

- - - - - - - - - 3.52 B - - - 4.76 B 2.96 B - - 1.14 B 1.28 B - - 1.59 B - - - 413 M - - - 64.1 M - - - - - - - - - - - - - - - - - - - - - - -

Book Value

- - - - 1.72 B 2.91 B - 4.02 B - 4.56 B - - - 5.63 B 3.74 B - - 1.07 B - - - 1.96 B - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Total Shareholders Equity

- - - - 1.72 B 2.91 B - 4.02 B - 4.56 B - - - 5.63 B 3.74 B - - -2.03 B -1.63 B - - -955 M - - - -300 M - - - -14.5 M - - - - - - - - - - - - - - - - - - - - - - -

All numbers in CNY currency

Balance Sheet is a fundamental financial report of I-Mab, providing a complete picture of the company’s financial position at a specific point in time. Unlike the income statement, which records the results of operations over a certain period, the balance sheet shows what assets the company owns, what liabilities it has to creditors, and what equity is available to the owners.

For an investor, the balance sheet is important because it allows assessing the company’s financial stability, understanding how much debt it carries, and how dependent it is on borrowed financing. It helps calculate key liquidity and leverage ratios. When analyzing, attention should be paid to the debt-to-equity ratio (Debt/Equity), the amount of cash on the balance sheet, and the ratio of current liabilities to liquid assets.

Features of balance sheet analysis
  • Vertical and horizontal analysis
    Vertical analysis shows the structure of the balance sheet as a percentage of total assets or liabilities, while horizontal analysis shows the dynamics of changes over multiple periods.
  • Asset quality
    It is important to evaluate not only the amount of assets but also their liquidity and realizability.
  • Accounting for off-balance sheet liabilities
    Some liabilities may not be directly reflected in the balance sheet, which requires additional attention.

Balance sheet of other industry stocks – Biotechnology

Issuer Price % 24h Market Cap Country
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada
Cleveland BioLabs, Inc. Cleveland BioLabs, Inc.
CBLI
- -7.31 % $ 49 M usaUSA
Five Prime Therapeutics, Inc. Five Prime Therapeutics, Inc.
FPRX
- - $ 1.77 B usaUSA
Aravive Aravive
ARAV
- -13.39 % $ 1.45 M usaUSA
Arena Pharmaceuticals Arena Pharmaceuticals
ARNA
- -6.81 % $ 3.04 B usaUSA
Biofrontera AG Biofrontera AG
BFRA
- -8.24 % $ 105 M germanyGermany
Catabasis Pharmaceuticals, Inc. Catabasis Pharmaceuticals, Inc.
CATB
- -6.97 % $ 657 M usaUSA
China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc.
CBPO
- 1.68 % $ 4.65 B chinaChina
Flexion Therapeutics, Inc. Flexion Therapeutics, Inc.
FLXN
- - $ 459 M usaUSA
Heat Biologics, Inc. Heat Biologics, Inc.
HTBX
- -5.76 % $ 99.8 M usaUSA
Kindred Biosciences, Inc. Kindred Biosciences, Inc.
KIN
- 0.11 % $ 419 M usaUSA
Shineco, Inc. Shineco, Inc.
TYHT
- -3.90 % $ 97.2 M chinaChina
Millendo Therapeutics, Inc. Millendo Therapeutics, Inc.
MLND
- -5.36 % $ 20.2 M usaUSA
Intec Pharma Ltd Intec Pharma Ltd
NTEC
- -12.45 % $ 17.7 M israelIsrael
Progenity, Inc. Progenity, Inc.
PROG
- -3.47 % $ 164 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Strongbridge Biopharma plc Strongbridge Biopharma plc
SBBP
- 1.52 % $ 136 M usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
Seneca Biopharma, Inc. Seneca Biopharma, Inc.
SNCA
- -1.19 % $ 28.7 M usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
Myovant Sciences Ltd. Myovant Sciences Ltd.
MYOV
- -0.04 % $ 2.62 B usaUSA
Trean Insurance Group Trean Insurance Group
TIG
- - $ 316 M usaUSA
Virpax Pharmaceuticals Virpax Pharmaceuticals
VRPX
- -45.12 % $ 2.85 M usaUSA
Metacrine Metacrine
MTCR
- - $ 24.2 M usaUSA
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
Генетико Генетико
GECO
- - - russiaRussia
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 56.8 0.94 % $ 1.63 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
ОЗОН Фармацевтика ОЗОН Фармацевтика
OZPH
- - - russiaRussia
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Galapagos NV Galapagos NV
GLPG
- - $ 1.83 B belgiumBelgium
Teligent, Inc. Teligent, Inc.
TLGT
- -13.85 % $ 16.1 M usaUSA
Viela Bio, Inc. Viela Bio, Inc.
VIE
- - $ 2.91 B usaUSA
Applied Molecular Transport Applied Molecular Transport
AMTI
- - $ 10.1 M usaUSA
Aphria Inc. Aphria Inc.
APHA
- -0.45 % $ 4.87 B canadaCanada
Aerpio Pharmaceuticals, Inc. Aerpio Pharmaceuticals, Inc.
ARPO
- -0.90 % $ 104 M usaUSA